Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
Healthcare
$2.03 +2.84%
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
52W Low $1.35High $4.60
Volume 1.12M
Average 1.37M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$83.25M
FY 2025 · Annual
Net Income
-$45.62M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| 14.82M | 14.29M | 24.62M | 48.54M | 81.84M | |
| 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
ELDN Earnings Waterfall · TTM
NASDAQ:ELDN · Revenue to Net Income
Key Ratios
EPS$-0.87
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$78.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.87, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 30, 2026 | |
| S-8 | S-8 filing | Sep 4, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 |
How much revenue does ELDN generate?
Eledon Pharmaceuticals, Inc. (ELDN) reported $0.00 of revenue in fiscal 2025.
Is ELDN profitable?
Eledon Pharmaceuticals, Inc. (ELDN) reported -$45.62M of net income.
Continue the stock analysis
Jump to another research area for this company.